Myoblast therapy: from bench to bedside.
Myoblasts are defined as stem cells containing skeletal muscle cell precursors. A decade of experimental work has revealed many properties of myoblasts, including the stability of resulting hybrid myofibers without immune suppression, the persistence of transgene expression, and the lack of tumorigenicity. Early phase clinical trials also showed that myoblast-based therapy is a promising approach for many intractable clinical conditions, including both muscle-related and non-muscle-related diseases. The potential application of myoblast therapy may be in the treatment of genetic muscle diseases, cardiomyocyte damaged heart diseases, and urinary incontinence. This review will provide an overview of myoblast biology, along with discussion of the potential application in clinical medicine. In addition, problems in current myoblast therapy and possible future improvements will be addressed.
Liu
Zhongmin
Z
Heart Center, Shanghai East Hospital, Tongji University, Shanghai 200120, China.
Wu
Yanling
Y
Chen
Bing-guan
BG
D000818:Animals; D009202:Cardiomyopathies / Q000628:therapy; D064987:Cell- and Tissue-Based Therapy; D018014:Gene Transfer Techniques; D006801:Humans; D020388:Muscular Dystrophy, Duchenne / Q000628:therapy; D032448:Myoblasts, Skeletal / Q000166:cytology* / Q000637:transplantation*; D014549:Urinary Incontinence / Q000628:therapy